Cargando…
2262. Ceftazidime–Avibactam vs. Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
BACKGROUND: Pharmacotherapy for carbapenem-resistant Enterobacteriaceae (CRE) infections is limited. There is a paucity of evidence to guide optimal management of CRE infections. Ceftazidime–avibactam, a novel cephalosporin/β-lactamase inhibitor, may be a reasonable alternative to colistin for CRE i...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811330/ http://dx.doi.org/10.1093/ofid/ofz360.1940 |